Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response.
Dimethyl fumarate induces necroptosis in colon cancer cells through glutathione depletion/ROS increase/MAPKs activation pathway.
FDA product review for daclizumab
[Prevalence of multiple sclerosis in the Region of Murcia].
Pediatric Multiple Sclerosis.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.
Social Support in Relation to Fatigue Symptoms Among Patients with Multiple Sclerosis.
Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.
The cell biology of CNS myelination.
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro.
Treating Post-traumatic Stress Disorder in Patients with Multiple Sclerosis: A Randomized Controlled Trial Comparing the Efficacy of Eye Movement Desensitization and Reprocessing and Relaxation Therapy.
The impact of multiple sclerosis relapse treatment on migration of effector T cells - Preliminary study.
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Voiding Dysfunction in Multiple Sclerosis.
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
[Immunomodulation and neuroprotection in optic neuritis].
Multiple Sclerosis and Catastrophic Health Expenditure in Iran.
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients
Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis.
Interferon-beta is a potent promoter of nerve growth factor production by astrocytes.
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Immunology of Multiple Sclerosis.
Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.

Pages